An observational study in Respiratory Disorders, sponsored by GlaxoSmithKline. Completed. Per ClinicalTrials.gov, last updated 2017-05-16.
Sponsored by GlaxoSmithKline · Observational
The purpose of this post-marketing surveillance is to detect adverse drug reactions (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy in the Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate.
513 studies on the registry are indexed under Respiration Disorders; 98 are open to participants now.
This study's enrollment of 2,116 is above the median of 239 across 207 observational studies indexed under Respiration Disorders.
Browse Respiration Disorders studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Japanese patients with asthma
Exclusion Criteria:
Patients with asthma prescribed fluticasone and salmeterol during study period
Drug: Salmeterol and Fluticasone
The number of incidence of adverse events in Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate
Time frame: 6 months
No study locations are listed for this record.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline